Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S.

FDA approves epcoritamab-bysp for follicular lymphoma indications

FDA approved epcoritamab-bysp with lenalidomide and rituximab for relapsed or refractory follicular lymphoma.

November 21, 2025

Alliance launches trial to study exercise in cancer patients

The Alliance for Clinical Trials in Oncology has launched a new clinical trial seeking to evaluate the feasibility of delivering a structured exercise program entirely through telehealth for patients with cancer receiving chemotherapy with the ultimate goal of reducing fatigue and disability.

November 14, 2025

Vol.51 No.42

Drugs & Targets

FDA approves Komzifti for r/r NPM1-mutated AML

FDA has granted full approval of Komzifti (ziftomenib) for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. Komzifti is the first and only once-daily, oral menin inhibitor approved for R/R NPM1-mutated AML, a devastating blood cancer with limited treatment options.

November 14, 2025

Vol.51 No.42

Cancer Policy

Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients

FDA announced six additional awardees under the Commissioner’s National Priority Voucher pilot program, which aims to accelerate review time for applications that are deemed to be advancing U.S. “national priorities” (The Cancer Letter, Oct. 24, June 20, 2025).

Researchers develop technique to track chemotherapy drug inside cells

Scientists face limitations in determining the results of drug effectiveness, as well as ensuring even distribution among all cancer cells because of the highly compact nature of tumors. Researchers are working to change that by giving chemotherapy drugs a kind of chemical “signal” to track them inside cells.

October 31, 2025

Vol.51 No.40

Drugs & Targets

FDA approves Blenrep combination for relapsed/refractory multiple myeloma after two or more lines of therapy

FDA approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

October 24, 2025

Vol.51 No.39

Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S.

YOU MAY BE INTERESTED IN

FDA approves epcoritamab-bysp for follicular lymphoma indications

Alliance launches trial to study exercise in cancer patients

FDA approves Komzifti for r/r NPM1-mutated AML

Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients

Researchers develop technique to track chemotherapy drug inside cells

FDA approves Blenrep combination for relapsed/refractory multiple myeloma after two or more lines of therapy

Renew today!

Subscriber content

Never miss an issue!

Login